Evidence map›Paper›PMID 33473219›Full record

ReviewNature reviews. Clinical oncology2021

Liquid biopsy enters the clinic - implementation issues and future challenges.

Michail Ignatiadis, George W Sledge, Stefanie S Jeffrey

2 registry-linked trialsOpen access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 679 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
679citing papers in PubMed, 3 pooled it
77.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06097156 recruitingnot on this mapstarted 2023, after this paper: background citation

Feasibility Evaluation of See.d Pre-Analytical Platform Performance: From Whole Blood to Plasma and SBS Slides for Liquid Biopsy Applications

TypeobservationalSponsorTethis S.p.A.Ran2023 to 2026Enrolled45ConditionsHealthy Participants, Breast Cancer
NCT06105177 recruitingnot on this mapstarted 2023, after this paper: background citation

Implementation of Up-front ctDNA Analysis Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - the Lungmarker² Study

Typeobservational_patient_registrySponsorCatharina Ziekenhuis EindhovenRan2023 to 2026Enrolled800ConditionsLung Cancer
3 · Its place in the literature

Who cites it

679 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

619 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Michail IgnatiadisDepartment of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium. michail.ignatiadis@bordet.be.ORCID http://orcid.org/0000-0002-4493-3748
George W SledgeDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0297-0775
Stefanie S JeffreyDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA. ssj@stanford.edu.ORCID http://orcid.org/0000-0003-4478-2764
Stanford Medicine · USStanford University · USUniversité Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour cells in peripheral blood have provided crucial insights into cancer biology and the metastatic process. More recently, advances in the detection and characterization of circulating tumour DNA (ctDNA) have finally enabled the introduction of liquid biopsy assays into clinical practice. The FDA has already approved several single-gene assays and, more recently, multigene assays to detect genetic alterations in plasma cell-free DNA (cfDNA) for use as companion diagnostics matched to specific molecularly targeted therapies for cancer. These approvals mark a tipping point for the widespread use of liquid biopsy in the clinic, and mostly in patients with advanced-stage cancer. The next frontier for the clinical application of liquid biopsy is likely to be the systemic treatment of patients with 'ctDNA relapse', a term we introduce for ctDNA detection prior to imaging-detected relapse after curative-intent therapy for early stage disease. Cancer screening and diagnosis are other potential future applications. In this Perspective, we discuss key issues and gaps in technology, clinical trial methodologies and logistics for the eventual integration of liquid biopsy into the clinical workflow.

Indexed as

Biomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNAHumansLiquid BiopsyMutationNeoplasm Recurrence, LocalNeoplasmsBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNA

Identifiers

PMID33473219
OpenAlexW3122882833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.